Use of ppar alpha agonists for the treatment of vascular and...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/216 (2006.01) A61K 31/192 (2006.01) A61P 9/00 (2006.01) A61P 13/00 (2006.01)

Patent

CA 2481371

Activation of peroxisome proliferator activated receptor alpha (PPAR.alpha.) by administration of therapeutic amounts of a PPAR.alpha. agonist, WY-14643, inhibits the proliferation of vascular smooth muscle cells, hepatoma cells and human renal proximal tubule cells. WY-14643 may be applicable as a medicament for the treatment of proliferative vascular disease (atherosclerosis, hypertension), revascularization-induced injury (restenosis) and chronic renal failure.

L'invention concerne l'activation du récepteur alpha activé par les proliférateurs de peroxysome (PPAR?) par administration de quantités thérapeutiques d'un agoniste de PPAR?.alpha., WY-14643, inhibant la prolifération de cellules du muscle lisse vasculaire, de cellules hépatomiques et de cellules tubulaires proximales rénales humaines. WY-14643 peut être utilisé comme un médicament destiné au traitement de maladies prolifératives (athérosclérose, hypertension), d'une blessure induite par revascularisation (resténose) et de l'insuffisance rénale chronique.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of ppar alpha agonists for the treatment of vascular and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of ppar alpha agonists for the treatment of vascular and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ppar alpha agonists for the treatment of vascular and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2057302

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.